NCT05660655 is a Phase 4 clinical trial of Baricitinib 4 MG Oral Tablet in Rheumatoid Arthritis, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

Who is sponsoring NCT05660655?

NCT05660655 is sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

What drugs are being tested in NCT05660655?

Interventions in NCT05660655: Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG.

What condition does NCT05660655 study?

NCT05660655 studies Rheumatoid Arthritis.

Is NCT05660655 still recruiting?

NCT05660655 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT05660655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

Completed Phase 4 Last updated 18 November 2023

What this trial tests

Phase 4 trial testing Baricitinib 4 MG Oral Tablet in Rheumatoid Arthritis in 94 participants. Completed in 30 September 2023.

Timeline

1 October 2022

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	94
Start date	1 October 2022
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	1 location across Bangladesh

Drugs / interventions tested

Baricitinib 4 MG Oral Tablet
Baricitinib 2 MG — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →

Sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Who can join

18 and older, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized controlled study. Baricitinib 4mg in one arm and Baricitinib 2mg in another arm will be used. Methotrexate 10mg per week in both arms will be used.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases.
Wang MJ, Zhang HL, Chen F, Guo XJ, et al · · 2024 · cited 43× · PMID 38890694 · DOI 10.1186/s40164-024-00527-1
Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country.
Islam MS, Choudhury MR, Azad MAK, Shahin MA, et al · · 2026 · PMID 41913302 · DOI 10.1186/s41927-026-00638-8

Verify or expand the search:

Other trials of Baricitinib 4 MG Oral Tablet

Trials testing the same drug.

NCT07279688 — Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica · Phase 3 · not yet recruiting
NCT06240351 — A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) · Phase 4 · active not recruiting
NCT04358614 — Baricitinib Therapy in COVID-19 · Phase 2, PHASE3 · completed

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh trials

Trials by the same sponsor.

NCT07507045 — Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh · NA · not yet recruiting
NCT07537634 — Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication · Phase 4 · not yet recruiting
NCT07161336 — Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA · Phase 2 · recruiting
NCT06960694 — Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis · Phase 2 · completed
NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05660655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05660655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing